Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
162 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma(GLOBRYTE) | recruiting | Phase 3 | 182 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY |
| 23 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06163534 | A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | recruiting | — | 500 | Tempus AIINDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07143487 | Family Communications After Genetic Testing | recruiting | N/A | 4,186 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | recruiting | N/A | 420 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Phase 2 | 461 | National Cancer Institute (NCI)NIH | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06075810 | A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | recruiting | Phase 1 | 48 | MBQ PharmaINDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 796 | DualityBio Inc.INDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer(TROPION-Lung14) | recruiting | Phase 3 | 582 | AstraZenecaINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | recruiting | Phase 3 | 750 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | recruiting | Phase 2 | 256 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT05235165 | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | recruiting | Phase 3 | 62 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Aug 25, 2026 | clinicaltrials |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | recruiting | Phase 3 | 288 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | recruiting | Phase 3 | 1,450 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 19, 2026 | clinicaltrials |
| NCT05640102 | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | recruiting | — | 111 | BeiGeneINDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer(HEAL-ABC) | recruiting | Phase 3 | 402 | NRG OncologyOTHER | 2 | Aug 4, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 681 | Astellas Pharma IncINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT05874414 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 98 | GenfitINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | recruiting | Phase 4 | 78 | TakedaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04185935 | Molecular Genetics Studies of Cancer Patients and Their Relatives | recruiting | — | 999,999 | City of Hope Medical CenterOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer(INSITE) | recruiting | — | 2,500 | Convergent Genomics, Inc.NETWORK | 2 | Jun 29, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT06950385 | Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis(SERENTA) | recruiting | Phase 3 | 168 | Rapamycin Holdings Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT01790152 | Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | recruiting | — | 420 | Children's Oncology GroupNETWORK | 4 | May 18, 2026 | clinicaltrials |
| NCT06824064 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer(VISTA-1) | recruiting | Phase 2 | 150 | Riboscience, LLC.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT06963723 | Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer(PROOF) | recruiting | N/A | 1,000 | Alliance Foundation Trials, LLC.OTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT07238088 | Active Mammography and Counseling(MAMO) | recruiting | N/A | 1,020 | University of Puerto Rico Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07215624 | Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study(STOP-VTE) | recruiting | — | 500 | Wake Forest University Health SciencesOTHER | 2 | Apr 8, 2026 | clinicaltrials |
| NCT03723928 | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | recruiting | N/A | 739 | SWOG Cancer Research NetworkNETWORK | 3 | Apr 2, 2026 | clinicaltrials |
| NCT07018869 | Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | recruiting | Phase 3 | 1,057 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 31, 2026 | clinicaltrials |
| NCT06418204 | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics(COSMIC) | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 2 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials